NCT07167160 Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
| NCT ID | NCT07167160 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Women's Hospital School Of Medicine Zhejiang University |
| Condition | Cervical Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 59 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 59 participants in total. It began in 2025-03-10 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Eligibility Criteria
Inclusion Criteria: 1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery; 2. Positive PD-L1 expression; 3. ECOG score ≤1 Exclusion Criteria: 1. Positive parametrium or surgical margin; 2. Incomplete radical surgery; 3. Residual target lesions; 4. Active autoimmune disease or autoimmune disease requiring systemic treatment; 5. Previous treatment with immune checkpoint inhibitors.
Frequently Asked Questions
Who can join the NCT07167160 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07167160 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07167160 currently recruiting?
Yes, NCT07167160 is actively recruiting participants. Visit ClinicalTrials.gov or contact Women's Hospital School Of Medicine Zhejiang University to inquire about joining.
Where is the NCT07167160 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07167160 clinical trial?
NCT07167160 is sponsored by Women's Hospital School Of Medicine Zhejiang University. The trial plans to enroll 59 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.